|
Society News Pages
1
2
3 |
Forward this page to
your friends
|
Black Tie
International:
Global Health Impact
Forum
Photos by: GMK/Blacktiemagazine.com
|
|
 |
|
Alex Charlton, President of Corporate
Relations, Cavendish Global,
Dr. Jonathan Sackier, President & Chief
Medical Officer, Cavendish Global,
Michael Moffat, Director of Family Office Relations,
Cavendish Global
Amir Dossal, Chairman, Global
Partnerships Forum |
|
Cavendish
Global Health Impact Forum
Global Health
Impact Forum: A unique platform for pro-social family offices
and foundations in support of the goals and
objectives of the United Nations System. A discrete,
peer-to-peer knowledge expansion and relationship building
environment
focused on health for a global network of over 150 leading
family offices and foundations. A world-class forum for
organizations actively
seeking to accelerate technological innovation and health
access through sustainable philanthropy, grant-making and
impact investing
Principal objectives of the Forum:
1. Champion and Share:
Provide a peer-to-peer setting for family offices and their
foundations to
champion and share information on sustainable philanthropy,
grant-giving and impact investing projects which they are
passionate about with other family offices from around the
world
2. Access Knowledge and Insight: Help family offices and
foundations identify the best scientific minds, accomplished
healthcare delivery professionals, philanthropic
organizations, health-policy
experts and compelling private sector companies with the
potential for transformational impact on disease prevention,
diagnosis and treatment
3. Partners for Action: Action-driven platform to establish
new partnerships and alliances for improved health outcomes
and access; utilizing information and communication
technologies (ICTs)
as a key enabler
Program highlights include:
Over 150 Family Investment Offices and
Foundations represented from North America, Europe, Asia,
Africa and Latin America!
Over 50 accomplished healthcare delivery professionals,
health-policy experts, and philanthropic
organizations reveal specific
programs driving meaningful improvements in health, health
access and medical outcomes on a regional or national basis!
Over 50 groundbreaking discoveries and innovations by
scientists and private-sector CEO’s revealing groundbreaking
discoveries
and technology with the potential for transformational
impact on disease prevention, diagnosis, treatment and
medical outcomes!
Senior partners from top-30 private equity firms and pro-social funds
participating in panel discussions (including Aisling
Capital, Arsenal Capital Partners, Bridges Ventures,
CityLight Capital,
Easton Capital, Domain Ventures, and SV Life Sciences)
|
|
 |
|
Dr. Roland Rich,
Executive Director, United Nations Office for Partnerships,
Amir Dossal, Chairman, Global
Partnerships Forum
Saralyn Mark, MD,
Ambassador Gyan Chandra Acharya, High Representative for the
Least Developed Countries, Landlocked Developing Countries
and Small Island Developing States
Mr. Gary Fowlie, Head, ITU Liaison Office to the UN |
|
 |
|
Mr. Peter
Samuelson, Chairman, Co-Founder and President, The Starlight
Children’s Foundation, Ms. Kay Koplovitz, Co-founder
Springboard Enterprises and Founder USA Network, Mr. Josh
Cohen, Co-Founder, Managing Director, City Light Capita, Mr.
Gregory C. Simon, Chief Executive Officer Poliwogg, Mr. Brian
Trelstad, Managing Director, Bridges Ventures, Ms. Liesel
Pritzker Simmons, Social entrepreneur, co-founder,
Blue Haven Initiative. |
|
 |
|
Keynote Speaker:
Professor the Lord Darzi of Denham |
|
 |
|
Mr. Gary
Fowlie, Head, ITU Liaison Office to the UN
Dr
Fiona Adshead, Director of Wellbeing and Public Health, Bupa |
|
 |
|
Zecki Dossal, Irene
Pritzer, Tas Dossal |
|
 |
|
Gerard Mc Keon,
Saralyn Mark |
|
 |
|
Peter
Samuelson,Founder, The Starlight Children’s Foundation
Ana Marina Lebada |
|
 |
|
Stephen Sahaya,
Amelia Quelas |
|
 |
|
Greg Simon,
Katherine Kirsch, Gregory Casagrande |
|
 |
|
Keynote Speaker: Mehmood Khan M.D. Executive Vice President
and Chief Scientific Officer, Global Research & Development at
PepsiCo.
Amir Dossal, Chairman, Global
Partnerships Forum |
|
|
|
Agenda |
Monday, May 5th:
Global Health Impact Forum and Gala Dinner, United Nations General
Assembly Hall |
Welcoming Remarks
Mr. Amir Dossal, Chairman, Global Partnerships Forum
Mr. Thomas Gass,
Assistant Secretary-General for Policy Coordination and
Inter-Agency Affairs, UN DESA
Dr. Roland Rich, Executive Director, United Nations Office for
Partnerships
!
Opening Keynotes
Ambassador Gyan Chandra Acharya, High Representative for the
Least Developed Countries, Landlocked Developing Countries
and Small Island Developing States
His Excellency Dr Hamadoun Touré, Secretary-General of the
International Telecommunication Union
Saralyn Mark, MD, a world renowned leader in women’s health,
is an endocrinologist, geriatrician and women’s health
specialist. She was the first Senior Medical Advisor to the
Office on Women’s Health within the Department of Health and
Human Services |
|
|
|
Panel II: Britain’s
best kept secret; opportunities to accelerate innovation
with the National Health Service (NHS)
Chaired by Professor Freddie Hamdy, Head of the Nuffield
Department of Surgery, Nuffield Professor of Surgery,
Professor of
Urology and Honorary Consultant Urological Surgeon at the
Oxford Radcliffe Hospitals and Fellow of Balliol College. He
has spent
the past 10 years as founding Chair of Urology and was
Director of the Division of Clinical Sciences, then Head of
Oncology at the
University of Sheffield.
Lord Darzi of Denham, Chairman of Departments of Surgery at
Imperial College London Professor Darzi holds the Paul
Hamlyn
Chair of Surgery at Imperial College London, the Royal
Marsden Hospital and the Institute of Cancer Research. He is
Director of the
Institute of Global Health Innovation at Imperial College
London and an Honorary Consultant Surgeon at Imperial
College Hospital
NHS Trust.
Mr. Miles Ayling, Director of Innovation, NHS England &
Chair of the NHS Innovation Challenge Prizes Expert Panel.
Whilst
working for the Department of Health and NHS England,
Director of Innovation, Mr. Ayling has been responsible for
a number of
significant healthcare reform programs including the
introduction of legislation on care trusts, delivery of
commissioning a patient
led NHS and the reconfiguration of services in Primary Care
Trusts.
Ms. Kate Bingham, Ms. Kate Bingham, Managing Partner, SV
Life Sciences, London. The SVLS team manages five private
venture capital funds with approximately $1.9 billion of
capital under management. The firm employs a diversified
strategy within
life sciences in order to selectively capitalize on an
expanding opportunity in biotech, medical devices and
health-care services.
Sir Andrew Cash, Chief Executive, Sheffield Trust, founding
Chair of the Foundation Trust Network (FTN) and previously
served as
Director General, Department of Health, England and co-chair
of the Department of Health/Ministry of Defence Partnership
Board.
He is a visiting Professor in Leadership and Development at
the Universities of Sheffield and York.
Sir Jonathan Michael, Chief Executive Oxford University
Hospitals NHS Trust and Trustee of the King's Fund. His
previous roles
include Managing Director of BT Health, Chief Executive of
Guys and St Thomas’s Hospitals NHS Foundation Trust and
Chief
Executive of University Hospitals Birmingham NHS Trust. |
|
|
Luncheon: United
Nations Delegates Dining Room
Keynote Speaker: Professor the Lord Darzi of Denham,
Professor Darzi holds the Paul Hamlyn Chair of Surgery at
Imperial College London, the Royal Marsden Hospital and the
Institute of Cancer Research. He is Director of the
Institute
of Global Health Innovation at Imperial College London and
an Honorary Consultant Surgeon at Imperial College Hospital
NHS Trust. He was knighted for his services in medicine and
surgery in 2002. In 2007, he was introduced to the United
Kingdom’s House of Lords as Professor the Lord Darzi of
Denham and appointed Parliamentary Under-Secretary of State
at the Department of Health. Professor Darzi served as the
United Kingdom’s Global Ambassador for Health and Life
Sciences. In 2013 he hosted the World Innovation Summit for
Health in Doha, Qatar, under the Patronage of Her
Highness Sheikha Moza bint Nasser al Missned and Qatar
Foundation.
!
Groundbreaking discoveries and innovations from Great
Britain:
Mr. William Allan, CEO Vascular Flow Technologies
Mr. Ian Paling, CEO CellCoTec
|
|
|
Panel III: How to
identify innovations with the potential for transformational
impact on disease outcomes and
ensure successful integration into medical practice:
Respected leaders from the world of private-equity and
highly
accomplished entrepreneurs will share secrets to identifying
innovations with the potential for transformational impact
and
making sure they get integrated into medical practice
Mr. Alexander Saint-Amand, President and CEO of GLG, the
world’s largest membership for professional learning and
expertise.
He is a founding member of the company and previously served
as its Chief Operating Officer. During his tenure and under
his
leadership, GLG has grown from a small start-up to one of
New York City’s most successful venture-backed companies,
having
facilitated over 1.5 million teaching and learning projects,
and now with over 20 offices in 12 countries
Mr. Aly Sheezar Jeddy, Partner, HealthCare & Institutional
Coverage, The Abraaj Group. Mr. Jeddy plays Group-wide
investment
and firm management roles as well as supporting the firm’s
investor relations activities in the United States. Mr Jeddy
joined
Abraaj after twenty years at McKinsey & Company where he was
a Senior Partner based in New York and Head of the Private
Equity and Principal Investing Practice in the Americas
Mr. Steve McLean, Arsenal Capital Partners; a progressive
private equity firm with $1.65 billion under management that
facilitates transformational growth and change through a
collaborative approach. Prior to joining Arsenal in 2010,
Mr.
McLean was a Managing Director at Courtagen Capital Group
and its predecessor companies where he invested in
healthcare companies
Mr. Adair Newhall, Principal, Domain Associates; Domain was
one of the first venture capital firms to exclusively invest
in
the life sciences sector. Domain has been involved in the
formation of more than 250 companies, with more than $2.7
billion in capital raised to-date
Mr. Stanton (Stan) J. Rowe, Chief Scientific Officer &
Corporate Vice President, Edwards Lifesciences and also
serves as
Corporate Vice President, Advanced Technology. He joined the
company in 2004 when Edwards acquired Percutaneous
Valve Technology, of which he was president and CEO and
helped to found in 1999. Previously, Rowe was Corporate Vice
President of Business Development and Strategic Planning for
Datascope and was Vice President of Business
Development for Johnson & Johnson’s Interventional Systems
Division (JJIS), responsible for the company’s coronary
stent development efforts
Andrew Schiff, M.D., Managing Director, Aisling Capital a
leading investment firm focused on novel approaches toward
the diagnosis, prevention, and treatment of life-threatening
illnesses. Prior to joining Aisling, Dr. Schiff practiced
internal
medicine at The New York Presbyterian Hospital where he
maintains his position as a Clinical Assistant Professor of
Medicine |
|
|
Groundbreaking
discoveries and innovations: Recent discoveries in
Neurodegenerative Diseases revealed; potential for
transformational impact on disease prevention, diagnosis and
treatment; Chairman, Dr. Jonathan Sackier
Dr. RJ Tesi, CEO FPRT Bio
Dr. Alan Snow, Chairman and CEO ProteoTech
Mr. Larry Tiffany, CEO DioGenix
4:45 PM
Groundbreaking discoveries and innovations: Recent
discoveries in Cancer revealed; potential for
transformational impact on
disease prevention, diagnosis and treatment; Chairman, Dr.
Jonathan Sackier
Dr. Graham Kelly, CEO Novogen
Mr. David Kalergis, CEO Diffusion
5:15 PM Mr. Tony Kuhn, CEO The Load Zero Foundation; Viral
Load Testing for the Developing World
5:30PM
Panel IV: “Be He@lthy, Be Mobile”
Chaired by Mr. Gary Fowlie, Head, ITU Liaison Office to the
UN. Global health policy leaders and internationally
respected mobile
technology and broadband innovators will provide insights to
the transformational impact of telemedicine, mobile health
and
broadband on health access and outcome
Jacob Kumaresan, Head of WHO NYC office
Dr Fiona Adshead, Director of Wellbeing and Public Health,
Bupa
Leslie Martinkovics*, Director, International Public Policy
& Regulatory Affairs, Verizon Communications, Inc.
Erik Augustson, Program Director, National Cancer Institute,
Tobacco Control Research Branch, Behavioral Research Program
6:30 PM
Gala Dinner: United Nations Delegates Dining Room
Special performance by Mr. John Oates, 2014 Rock and Roll
Hall of Fame Inductee
!
Keynote Speaker: Mehmood Khan M.D. Executive Vice President
and Chief Scientific Officer, Global Research & Development at
PepsiCo. As chief scientific officer, Mehmood leads
company-wide research and development (R&D); recruits highly
regarded
clinical scientists, global health leaders and medical
experts; launches research projects with leading
universities; and opens
advanced R&D facilities. Prior to joining PepsiCo, Mehmood
was as a faculty member at the Mayo Clinic and Mayo Medical
School in Rochester, Minn., serving as director of the
Diabetes, Endocrine and Nutritional Trials Unit in the
endocrinology division.
He also spent nine years leading programs in diabetes,
endocrinology, metabolism and nutrition for the Hennepin
County Medical
Center in Minneapolis |
|
|
|
Tuesday, May 6th:
Global Health Impact Forum and Tribute Reception, United
Nations ECOSOC Chamber |
Welcoming Remarks
Mr. Gary Fowlie, Head, ITU Liaison Office to the UN
Opening Keynote
Scott Parazynski, Astronaut, Everest Climber, Physician, and
Telemedicine Champion
Mr. John H. Friedman, Founding and Managing Partner, Easton
Capital, a leading private equity firm focused only on
those opportunities that offer services or products that can
materially improve the healthcare people receive or reduce
its
cost
10:30 AM
Panel I: The transformational impact of telemedicine,
broadband and mobile health on health access and
outcomes; Global health policy leaders and internationally
respected mobile technology and broadband innovators will
provide insights to the transformational impact of
telemedicine, mobile health and broadband on health access
and
outcomes
!
Mr. Yasuhiro Oishi, President, Kyocera Communications Inc.
Dr. Muzibul Khan, Corporate and Technology Planning, Kyocera
Communications, Inc.
Steve Shaya M.D. of family office owned J&B Medical and member
of ’Pietas’, the global nonprofit dedicated to
providing telemedicine solutions for rural and indigenous
communities
11:00 AM
Groundbreaking discoveries and innovations: Recent
discoveries in Nutrition revealed: Mr. Ethan Brown, CEO &
Founder,
Beyond Meat: “Would we continue to raise and eat animals in
such staggering numbers if we could make the same thing from
plants?” Insights revealing the importance and momentum of
plant-based protein. Founded in 2009 by Ethan Brown and
Brent
Taylor, Beyond Meat is supported by pro-social investors
that share a passion and drive for changing the way the
world gets its
protein, and include, among others, Bill Gates, Twitter
co-founders Biz Stone and Evan Williams; investment firms
Kleiner-Perkins
Caufield & Beyers, Morgan Creek Capital and Closed Look
Capital; Seth Goldman, the founder of Honest Tea and the
Humane
Society of the United States. |
|
|
Panel II: How to win
the battle against diabetes and obesity: Accomplished
scientists, philanthropists, health policy experts
and senior executives from innovative private-sector
companies will reveal specific initiatives that are helping
to win the battle
against diabetes and obesity and explore opportunities to
bring about lasting change
Chaired by Mr. David Jones, Jr. Director of Humana, The
Humana Foundation, Inc., Board member of the National
Committee on
U.S.-China Relations and Chairman of Chrysalis Ventures. Mr.
Jones is a well-respected voice in healthcare business,
innovation
and education. Mr. Jones brings a strong and well-rounded
background in business, law and banking to his work at
Chrysalis
Ventures, which he founded in 1993. David is active in civic
and charitable affairs on both national and local levels
Mehmood Khan, M.D. Executive Vice President and Chief
Scientific Officer, Global Research & Development at PepsiCo As
chief
scientific officer, Mehmood leads company-wide research and
development (R&D); recruits highly regarded clinical
scientists,
global health leaders and medical experts; launches research
projects with leading universities; and opens advanced R&D
facilities
Mr. Paul LaViolette, Managing Partner SV Life Sciences and
previously Chief Operating Officer at Boston Scientific
Corporation
(BSC), also served at BSC as COO, Group President,
President-Cardiology and President-International. During his
15 years at
BSC, he served as COO, Group President, President-Cardiology
and President-International. Mr. LaViolette previously held
marketing and general management positions at CR Bard, and
various marketing roles at Kendall (Covidien)
Saralyn Mark, M.D. Saralyn Mark, MD, a world renowned leader
in women’s health, is an endocrinologist, geriatrician and
women’s health specialist. She was the first Senior Medical
Advisor to the Office on Women’s Health within the Department
of
Health and Human Services
Dr. Nandan Padukone, Ph.D., MBA, Vice President Office of
Commercialization & Ventures, (OCV) Joslin Diabetes
Institute of
Harvard Medical School. Dr. Padukone helped launch the OCV
as a business center of Joslin Diabetes Center to create
strategic
relationships with industry and leverage Joslin’s
world-leading expertise in diabetes-directed research and
clinical care
Maj. Gen. Gale Pollock, Former Deputy Surgeon General of the
United Sates Army, and served as Acting Surgeon General of
the
Army as well as the 22nd Chief of the Army Nurse Corps. The
Acting Surgeon General position made Maj. General Pollock
one of
the few women in the US to run a Fortune 50 sized
organization with a $9.7B budget
Dr. Robert E. Ratner is Chief Scientific & Medical Officer for
the American Diabetes Association, the nation’s largest
voluntary health
organization leading the fight to Stop Diabetes®. Dr. Ratner
provides leadership and oversight of scientific and medical
activities
including research, clinical affairs, program recognition and
certification, medical information and professional education |
|
|
Groundbreaking
discoveries and innovations panel discussions: Recent
discoveries in Infectious Diseases revealed;
potential impact on disease prevention, diagnosis and
treatment; Chairman, Dr. Jonathan Sackier
Dr. Michel Bazinet, M.D. CEO Replicor
Mr. John Reisky de Dubnic, CEO Cavidi
Mr. Michael Smith, CFO Safe Eggs
Dr. Mark Benedyk, CEO Telephus Medical
Mr. Clifford Stocks, CEO Theraclone Sciences
6:30 PM
Tribute Reception: United Nations Delegate Dining Room
!
Special performance by Jihae; New York City-based
singer/composer/multimedia artist |
|
|
Groundbreaking
discoveries and innovations panel discussions: Recent
discoveries in Infectious Diseases revealed;
potential impact on disease prevention, diagnosis and
treatment; Chairman, Dr. Jonathan Sackier
Dr. Michel Bazinet, M.D. CEO Replicor
Mr. John Reisky de Dubnic, CEO Cavidi
Mr. Michael Smith, CFO Safe Eggs
Dr. Mark Benedyk, CEO Telephus Medical
Mr. Clifford Stocks, CEO Theraclone Sciences
6:30 PM
Tribute Reception: United Nations Delegate Dining Room
!
Special performance by Jihae; New York City-based
singer/composer/multimedia artist |
|
|
|
Wednesday, May 7th:
Global Health Impact Forum and Reception, Rockefeller
University, Caspary Auditorium |
Registration –
Rockefeller University, Caspary Auditorium,
Coffee and Refreshments
8:45 AM
Welcoming Remarks
Mr. Zac Russell, Trustee, The Russell Family Foundation
Mr. Paul Reverdy and Ms. Christine Odabashian, Robotic
Exoskeleton, Princeton University
Dr Murali Prahalad, PH. D., CEO Epic Sciences
Panel I: Ground-breaking approaches to discovery that are
transforming innovation and outcomes: Case-studies reveal
the
methods that are making a difference
The National Institutes of Health Oxford-Cambridge Scholars
Program is having an extraordinary impact on the
development of the next generation of scientists. The Panel
will reveal the ground-breaking methods and impact of this
unique
program.
The Angiogenesis Foundation is the world’s first nonprofit
organization dedicated to conquering disease using a new
approach based on angiogenesis, the growth of new capillary
blood vessels in the body. The Foundation has developed a
unique social enterprise model based on international
collaborations with leading medical academic centers,
biopharmaceutical
companies, and government agencies, including the National
Institutes of Health, National Cancer Institute, and the
Food and
Drug Administration
William W. Li M.D.; President, Medical Director, and
Co-founder of the Angiogenesis Foundation; Will trained in
the lab of Dr.
Judah Folkman, pioneer of the angiogenesis field, and has
been actively engaged in angiogenesis research and clinical
development for 22 years
Vincent W. Li M.D., M.B.A.; COO, Scientific Director, and
Co-founder of the Angiogenesis Foundation; physician,
scientist,
social entrepreneur and innovator; honored as HHMI Research
Fellow and Harvard Business School Social Enterprise Fellow
Michael Lenardo M.D.; Co-founder of the National Institutes
of Health Oxford-Cambridge Scholars Program; Section Chief
at
Laboratory of Immunology, NIAID, NIH
Richard Siegel MD PhD, Co-founder of the National Institutes
of Health Oxford-Cambridge Scholars Program; Clinical
Director
of the National Institutes of Arthritis And Musculoskeletal
Diseases
Ms. Arianne Richard, an NIH-Cambridge Scholar
10:00 AM
Mr. David Auerbach, CEO Sanergy: In the slums of Nairobi,
millions of inhabitants rely on makeshift sanitation
facilities. The
World Health Organization estimates that 2.6 billion people
worldwide lack access to hygienic toilets, causing the
spread of
disease. David Auerbach thinks the private sector can help. |
|
|
|
Wednesday, May 7th:
Global Health Impact Forum and Reception, Rockefeller
University, Caspary Auditorium |
Panel II: New York
Academy of Sciences hosted panel, “Innovative Models of
Funding for High Risk Disease”
Chaired by Mr. Ellis Rubinstein, President and Chief
Executive Officer, The New York Academy of Sciences. The New
York Academy
of Sciences CEO, Ellis Rubinstein, and a world class panel
of accomplished experts will provide insights into how to
leverage
investments in high risk areas of disease research such as
neurodegenerative diseases and specifically Alzheimer’s.
While research in
disease prevention, treatment and drug development can be
high risk, under the right circumstances, philanthropists
will support such
work. We have been honored to organize a panel addressing
the newest thinking in social investment for high risk
research
Mr. Labeeb Abboud, Senior Vice President Business
Development and Strategy & General Counsel, IAVI; Fund
Manager, Global
Health. Mr. Abboud is responsible for the legal,
intellectual property and risk-management considerations
associated with IAVI’s
operations and partnerships. He also oversees the
organization’s business development efforts. Prior to joining
IAVI, Mr. Abboud
served as general counsel to Atriax, a London-based
electronic marketplace for foreign exchange products and as
group counsel to
American Express Bank, Ltd. Mr. Abboud is currently vice
chair of the Rainforest Alliance, a director of Shackleton
Schools and
NEPCon and a member of the Council on Foreign Relations
Dr. Andrew Lo, PhD, Charles E. and Susan T. Harris Professor
of Finance; Director, Laboratory for Financial Engineering,
MIT Sloan
School of Management. Prior to MIT Sloan, he taught at the
University of Pennsylvania Wharton School as the W.P. Carey
Assistant
Professor of Finance from 1984 to 1987, and as the W.P.
Carey Associate Professor of Finance from 1987 to 1988. A
former governor
of the Boston Stock Exchange, he is currently a Research
Associate of the National Bureau of Economic Research; a
member of the
OFR Financial Research Advisory Committee, the New York
Federal Reserve Board’s Financial Advisory Roundtable, and
FINRA’s
Economic Advisory Committee
Mr. Pablo Legorreta, Founder and Chief Executive Officer,
Royalty Pharma. Mr. Legorreta founded Royalty Pharma in
1996, after
creating and managing two “proof of principle” investment
vehicles in 1993 and 1994 that invested in royalty interests
in two leading
biotechnology products. Prior to founding these investment
vehicles, Mr. Legorreta spent ten years at Lazard Frères
where he
provided cross-border merger and acquisition and corporate finance
advisory services to US and European corporations
Dr. Sam Hall, PhD, Associate, Apple Tree Partners. Dr. Hall
has over a decade of experience in the life sciences across
roles as a
private equity investor, investment banker and basic
scientist. Prior to joining Apple Tree in 2013, he was a
researcher at the University
of Cambridge in the UK, where his work focused on novel
therapeutic strategies for autoimmune diseases. Previously
Dr. Hall was a
member of the investment team at Symphony Capital, a private
equity firm dedicated to investments in biopharmaceutical
development
Ms. Melissa Stevens, Deputy Executive Director, FasterCures
a nonprofit think tank and center of the Milken Institute
that works
across sectors to improve the effectiveness and efficiency of
the medical research enterprise, and accelerate the
discovery and
development of new treatments for deadly and debilitating
diseases. Ms. Stevens manages planning and implementation of
FasterCures programs and directs the organization’s medical
philanthropy efforts including the Philanthropy Advisory
Service |
|
|
Wednesday, May 7th: Global Health Impact Forum and
Reception, Rockefeller University, Caspary Auditorium
Program Summary |
0 AM
Groundbreaking discoveries and innovations panel
discussions: Recent discoveries in Neurodegenerative
Diseases revealed;
potential impact on disease prevention, diagnosis and
treatment; Chairman, Dr. Jonathan Sackier
Mr. Stephen L. Hurst, CEO Savant HWP
Mr. Gerald Commisiong, CEO Amarantus BioScience
Ms. Marie Wesselhoft, CEO MSDx
Professor Malcolm Horne, Managing Director Global Kinetics
12:45 PM
!
Luncheon: Rockefeller University
2:00 PM
Groundbreaking discoveries and innovations panel
discussions: Recent discoveries in Enabling Platform
Technologies
revealed; potential impact on disease prevention, diagnosis
and treatment; Chairman, Mr. Alex Charlton
Dr. Trevor Castor, CEO Aphious
Dr. Steven Tregay, Forma Therapeutics
Mr. Richard T. Schumacher, CEO Pressure BioScience
2:50 PM
Groundbreaking discoveries and innovations panel
discussions: Recent discoveries in Cancer revealed;
potential impact on
disease prevention, diagnosis and treatment; Chairman, Mr.
Alex Charlton
Mr. George Colberg, M.D. CEO Kalos Therapeutics
Dr. George Thomas, PhD. CEO Marsala Biotech |
|
|
|
Wednesday, May 7th:
Global Health Impact Forum and Reception, Rockefeller
University, Caspary Auditorium |
|
Groundbreaking discoveries and innovations panel
discussions: Recent discoveries in Molecular Diagnostics
revealed;
potential impact on disease prevention, diagnosis and
treatment; Chairman, Dr. Jonathan Sackier
Mr. David Weaver, CEO Blaze Medical Devices
Dr. Eytan R. Barnea, MD FACOG, S.I.E.P. Chairman The Society
for the Investigation of Early Pregnancy
4:00 PM
Groundbreaking discoveries and innovations panel
discussions: Recent Discoveries in Infectious Diseases
revealed; potential
impact on disease prevention, diagnosis and treatment;
Chairman, Dr. Jonathan Sackier
Dr. David Huizenga, CEO Klaren Technologies
Mr. Kenneth Kelley, CEO PaxVax
Dr. Brett Baker, CEO Microbion Corporation
6:30 PM
Cavendish Awards Reception: Rockefeller University, Benjamin
and Irma G. Weiss Building
Family Office Panel: "What makes a grant great or
philanthropic gift? Family office insight to grant and
philanthropy requests that
family offices and their foundations want to fund. Family offices
will reveal their favorite grants and philanthropic gifts,
what made
them great and provide insights into what makes a grant
application compelling.”
Chaired by Mr. Gregory C. Simon, Chief Executive Officer
Poliwogg; Mr. Simon has held senior positions in both houses
of
Congress and the White House and led FasterCures/The Center
for Accelerating Medical Solutions, the national patient
advocacy
nonprofit
Mr. Jesse H. Ausubel, Director of the Program for the Human
Environment of The Rockefeller University
Ms. Kedge Martin, Co-founder of Longbow, Ms. Martin a
founder member of TRH Duke and Duchess of Cambridge and
Prince
Harry’s Charities Forum, and formerly CEO of Sentebale,
Prince Harry’s charity for African orphans
Ms. Ghislaine Maxwell, Founder The TerraMar Project
Ms. Irene Pritzker, President, IDP Foundation, dedicated to
developing programs in education that are sustainable and
move away
from aid dependent model
Steve Shaya, M.D., Dr. Shaya’s family founded and own J&B
Medical, he is als |
|
|
|
Back To
Society News |
|
| |
|